^
    Apply
    A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations (NCT05588141)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    05/16/2023
    Primary completion :
    08/01/2025
    Completion :
    08/02/2029
    IDH1 • IDH2
    |
    IDH2 mutation
    |
    zotiraciclib (TG02)
    A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors (BG-68501-101) (NCT06257264)
    Phase 1
    BeiGene
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    03/11/2024
    Primary completion :
    02/28/2028
    Completion :
    02/28/2028
    HER-2
    |
    HER-2 negative
    |
    fulvestrant
    Study of AVZO-021 in Patients with Advanced Solid Tumors (ARTS-021-1001) (NCT05867251)
    Phase 1/2
    Avenzo Therapeutics, Inc.
    Recruiting
    Last update posted :
    02/05/2025
    Initiation :
    08/30/2023
    Primary completion :
    01/31/2028
    Completion :
    01/31/2030
    HER-2 • CCNE1
    |
    HER-2 negative
    |
    Ibrance (palbociclib) • carboplatin • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • Trodelvy (sacituzumab govitecan-hziy) • AVZO-021
    Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (INX-315-01) (NCT05735080)
    Phase 1/2
    Incyclix Bio
    Recruiting
    Last update posted :
    05/22/2024
    Initiation :
    03/28/2023
    Primary completion :
    12/01/2025
    Completion :
    06/01/2026
    HER-2 • ER • CCNE1
    |
    HER-2 negative • CCNE1 amplification
    |
    INX-315
    PF-07104091 as a Single Agent and in Combination Therapy (NCT04553133)
    Phase 1/2
    Pfizer
    Active, not recruiting
    Last update posted :
    05/16/2024
    Initiation :
    09/16/2020
    Primary completion :
    03/06/2025
    Completion :
    03/06/2025
    HER-2
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
    |
    Ibrance (palbociclib) • fulvestrant • letrozole • tagtociclib (PF-07104091)
    (VELA) Study of BLU-222 in Advanced Solid Tumors (NCT05252416)
    Phase 1/2
    Blueprint Medicines Corporation
    Recruiting
    Last update posted :
    04/23/2024
    Initiation :
    04/07/2022
    Primary completion :
    11/30/2025
    Completion :
    09/30/2026
    HER-2 • CCNE1
    |
    HER-2 negative • CCNE1 amplification
    |
    carboplatin • Kisqali (ribociclib) • fulvestrant • BLU-222
    A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) (NCT05168904)
    Phase 1/2
    Cyclacel Pharmaceuticals, Inc.
    Suspended
    Last update posted :
    02/08/2024
    Initiation :
    10/22/2021
    Primary completion :
    10/01/2024
    Completion :
    12/01/2024
    BRAF • CDK9
    |
    fadraciclib (CYC065)
    A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma (NCT04983810)
    Phase 1/2
    Cyclacel Pharmaceuticals, Inc.
    Recruiting
    Last update posted :
    01/25/2024
    Initiation :
    07/12/2021
    Primary completion :
    04/30/2025
    Completion :
    06/30/2025
    CDK9
    |
    fadraciclib (CYC065)
    To Evaluate the Efficacy and Safety of TQB3616 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Previously Untreated Hormone-receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer (NCT05365178)
    Phase 3
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Active, not recruiting
    Last update posted :
    12/29/2023
    Initiation :
    07/01/2022
    Primary completion :
    06/01/2024
    Completion :
    06/01/2026
    HER-2
    |
    HR positive • HER-2 negative • PTEN mutation + HR positive
    |
    fulvestrant • culmerciclib (TQB3616)
    Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. (NCT05905341)
    Phase 1
    Pfizer
    Withdrawn
    Last update posted :
    11/08/2023
    Initiation :
    01/15/2024
    Primary completion :
    04/14/2026
    Completion :
    04/13/2028
    HER-2
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    fulvestrant • PF-07224826
    First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer (NCT05304962)
    Phase 1
    Regor Pharmaceuticals Inc.
    Recruiting
    Last update posted :
    10/13/2023
    Initiation :
    03/04/2022
    Primary completion :
    02/28/2024
    Completion :
    08/28/2024
    HER-2 • PIK3CA • CDK4
    |
    HER-2 negative • PIK3CA mutation
    |
    GDC-4198
    Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC (NCT05191004)
    Phase 1/2
    Nuvation Bio Inc.
    Withdrawn
    Last update posted :
    07/11/2023
    Initiation :
    09/01/2022
    Primary completion :
    06/01/2025
    Completion :
    09/01/2026
    HER-2
    |
    HER-2 negative
    |
    fulvestrant • inixaciclib (NUV-422)
    Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer (NCT05780567)
    Phase 3
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Recruiting
    Last update posted :
    04/21/2023
    Initiation :
    03/30/2023
    Primary completion :
    12/01/2026
    Completion :
    01/01/2027
    HER-2
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    tamoxifen • letrozole • anastrozole • culmerciclib (TQB3616)
    Dose Escalation and Expansion Study of SYH2043 in Patients With Advanced Malignant Tumors (NCT05728541)
    Phase 1
    CSPC Ouyi Pharmaceutical Co., Ltd.
    Not yet recruiting
    Last update posted :
    02/17/2023
    Initiation :
    03/01/2023
    Primary completion :
    02/01/2026
    Completion :
    03/01/2026
    HER-2 • ER
    |
    SYH2043
    Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma (STEAM) (NCT03224104)
    Phase 1
    European Organisation for Research and Treatmen...
    Completed
    Last update posted :
    05/31/2022
    Initiation :
    06/12/2018
    Primary completion :
    05/05/2022
    Completion :
    05/05/2022
    IDH1 • IDH2 • MCL1 • CDK9
    |
    IDH1 R132H • IDH1 R132
    |
    temozolomide • zotiraciclib (TG02)
    TQB3616 Capsules Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer in Clinical Trail (NCT05375461)
    Phase 3
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Recruiting
    Last update posted :
    05/16/2022
    Initiation :
    03/18/2022
    Primary completion :
    12/01/2023
    Completion :
    12/01/2023
    HER-2 • ER
    |
    ER positive • HER-2 negative • ER positive + HER-2 negative
    |
    fulvestrant • culmerciclib (TQB3616)
    A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors (NCT00999401)
    Phase 1
    Cyclacel Pharmaceuticals, Inc.
    Completed
    Last update posted :
    12/22/2021
    Initiation :
    04/01/2009
    Primary completion :
    07/16/2019
    Completion :
    08/13/2019
    BRCA
    |
    BRCA mutation
    |
    sapacitabine (CYC682) • seliciclib (CYC202)
    Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma (NCT02942264)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    09/28/2021
    Initiation :
    12/14/2016
    Primary completion :
    08/26/2020
    Completion :
    08/26/2020
    TP53 • ATRX
    |
    temozolomide • zotiraciclib (TG02)
    A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer (NCT04796623)
    Phase 2
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Recruiting
    Last update posted :
    03/15/2021
    Initiation :
    02/04/2021
    Primary completion :
    01/31/2023
    Completion :
    01/31/2023
    HER-2
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    fulvestrant • culmerciclib (TQB3616)
    A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer (TQB3616-II-01) (NCT04773418)
    Phase 2
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Recruiting
    Last update posted :
    02/26/2021
    Initiation :
    02/04/2021
    Primary completion :
    01/31/2023
    Completion :
    01/31/2023
    HER-2
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    fulvestrant • culmerciclib (TQB3616)
    A Phase I Study of TQB3616 on Tolerance and Pharmacokinetics (NCT03850873)
    Phase 1
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Unknown status
    Last update posted :
    02/22/2019
    Initiation :
    03/01/2019
    Primary completion :
    09/30/2020
    Completion :
    09/30/2021
    HER-2 • ER
    |
    culmerciclib (TQB3616)